Imvotamab

Sanofi has agreed to acquire Dren Bio's DR-0201, a first-in-class bispecific myeloid cell engager that induces deep B-cell depletion, for an upfront payment of $600 million.

The global rheumatoid arthritis market is projected to grow from $28 billion in 2024 to $34.7 billion by 2035, with a CAGR of 1.97%, fueled by advancements in biologics and targeted therapies.

IGM Biosciences has stopped the development of imvotamab and IGM-2644 after Phase 1b trials showed insufficient B cell depletion in rheumatoid arthritis and lupus patients.

BMO Capital has downgraded IGM Biosciences from Outperform to Market Perform, reducing the price target from $21 to $2, after the company announced the discontinuation of imvotamab and IGM-2644 in autoimmune diseases due to insufficient B cell depletion in Phase 1b studies.

Bispecific antibodies represent a significant advancement in cancer immunotherapy, targeting both tumor antigens and immune cells to enhance cytotoxicity without requiring patient-derived cells like CAR-T therapy.